Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 12, 2006, Pages 1814-1820

  Li, Jie ^a,b   Chen, Xiaoping ^a   Dong, Xuesong ^c   Xu, Zongzhen ^b   Jiang, Hongchi ^c   Sun, Xueying ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Shandong Provincial Owned Hospital   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell growth; Hepatocellular carcinoma; Meloxicam; Selective COX 2 inhibitor

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FAS ANTIGEN; FAS LIGAND; MELOXICAM; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 33750483320     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04366.x     Document Type: Article

References (37)

1. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 1999; 45: 730-2.
2. Tucker ON, Dannenberg AJ, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999; 59: 987-90.
3. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-96.
4. Sung JJ, Leung WK, Go MY et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000; 157: 729-35.
5. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-8.
6. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin and the risk of fatal colon cancer. N. Engl. J. Med. 1991; 325: 1593-6.
7. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 1995; 333: 609-14.
8. Thun MJ, NamBoodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993; 53: 1322-7.
9. Bae SH, Jung ES, Park YM et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin. Cancer Res. 2001; 7: 1410-18.
10. Huang DS, Shen KZ, Wei JF, Liang TB, Zheng SS, Xie HY. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through Bcl-2. World J. Gastroenterol. 2005; 11: 204-7.
11. Cheng J, Imanishi H, Amuro Y, Hada T. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int. J. Cancer 2002; 99: 755-61.
12. Chen HS, Kaneko S, Girones R et al. The woodchuck hepatitis virus X-gene is important for establishment of virus infection in woodchucks. J. Virol. 1993; 67: 1218-26.
13. Cheng J, Hada T. The significance of COX-2 and COX-2 inhibitors in liver fibrosis and liver cancer. Curr. Med. Chem. Anti-Inflamm. Anti-Allergy Agents 2005; 4: 199-206.
14. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J. Biol. Chem. 1994; 269: 11769-75.
15. Koga H, Sakisaka S, Ohishi M et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation. Hepatology 1999; 29: 688-96.
16. Shiota G, Okubo M, Noumi T et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 407-12.
17. Cheng AS, Chan HL, Leung NW et al. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. Aliment. Pharmacol. Ther. 2002; 16: 251-60.
18. Murata H, Tsuji S, Tsujii M et al. Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells. Lab. Invest. 2004; 84: 1050-9.
19. Horani MH, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promotor activity in cultured hepatoma cell line HepG2. Metabolism 2004; 53: 174-81.
20. Cheng J, Imanishi H, Liu W et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase-2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci. 2004; 95: 666-73.
21. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 2002; 277: 50081-6.
22. Teh SH, Hill AK, Foley DA et al. COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J. Cell. Biochem. 2004; 91: 796-807.
23. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogigagis D, O'Brien PE. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 2001; 48: 660-6.
24. Tsubouchi Y, Mukai S, Kawahito YM et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. 2000; 20: 2867-72.
25. Goldman AP, Williams CS, Sheng H et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998; 19: 2195-9.
26. Connolly KM, Bogdanffy MS. Evaluation of proliferating cell nuclear antigen (PCNA) as an endogenous marker of cell proliferation in rat liver: a dual-stain comparison with 5-bromo-2′-deoxyuridine. J. Histochem. Cytochem. 1993; 41: 1-6.
27. Rahman MA, Dhar DK, Masungaga R, Yamanoi A, Kohno H, Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res. 2000; 60: 2085-9.
28. Cheng AS, Chan HLY, Leung W, Wong N, Johnson PJ, Sung JJY. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int. J. Oncol. 2003; 23: 113-19.
29. Kondo M, Yamamoto H, Nagano H et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res. 1999; 5: 4005-12.
30. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997; 14: 629-40.
31. Umar A, Buermeyer AB, Simon JA et al. Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis. Cell 1996; 87: 65-73.
32. Song X, Lin HP, Johnson AJ et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 2002; 94: 585-91.
33. Crew TE, Elder DJ, Paraskeva C. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 2000; 21: 69-77.
34. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002; 62: 6323-8.
35. Muller M, Krammer PH. Integrated cell function: apoptosis. In: Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, Shafritz DA, eds. The Liver: Biology and Pathology. Philadelphia: Lippincott Williams & Wilkins, 2001; 187-205.
36. Kern MA, Schubert D, Sahi D et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36: 885-94.
37. Cheng AS, Chan HL, To KF et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int. J. Oncol. 2004; 24: 853-60.